怀孕期间的血栓性血栓塞性紫外线:综合性综述
1Department of Obstetrics and Gynecology, College of Medicine, 48023 Imam Abdulrahman Bin Faisal University , Al Khobar, Kingdom of Saudi Arabia.
Journal of perinatal medicine
|April 16, 2025
概括
怀孕期间的血栓性血栓性缺血性紫外线 (TTP) 是由ADAMTS13缺乏引起的严重疾病. 迅速的治疗性血交换和跨学科的护理对于优化母亲和胎儿的结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 产科 产科 产科 产科 产科
- 遗传学 是一个遗传学.
背景情况:
- 血栓性血栓塞性紫色素 (TTP) 是一种罕见的,危及生命的溶血性疾病.
- 它涉及微血管病性血液溶解性贫血 (MAHA),血栓细胞缺血和微血管血栓症.
- 由于ADAMTS13活动减少,怀孕会加剧TTP.
研究的目的:
- 审查妊娠期间TTP的病因学,诊断和管理.
- 突出临床挑战,并强调最佳的患者护理.
- 为了改善TTP怀孕中母亲和胎儿的结果.
主要方法:
- 文献综述专注于怀孕期间的TTP.
- 对诊断标准和临床表现的分析.
- 评估治疗策略,包括血交换.
主要成果:
- 在TTP的基础上存在ADAMTS13缺陷,导致vWF多元积累和血小板聚合.
- 由于影响ADAMTS的生理变化,怀孕带来了独特的风险13.
- 治疗性血交换 (TPE) 是管理的基石.
结论:
- 怀孕中的TTP需要高度的临床警和及时干预.
- 跨学科的护理对于管理这种复杂的疾病至关重要.
- 及时的TPE和协作管理可以提高孕产妇和胎儿的存活率.
相关概念视频
Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
Clot Retraction and Fibrinolysis
2.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.9K


